The online version of this article (doi:10.1007/s00270-013-0826-5) contains supplementary material, which is available to authorized users.
A new melphalan hemoperfusion filter (GEN 2) was evaluated in a simulated-use porcine model of percutaneous hepatic perfusion (PHP). The current study evaluated melphalan filtration efficiency, the transfilter pressure gradient, and the removal of specific blood products.
A porcine PHP procedure using the GEN 2 filter was performed under Good Laboratory Practice conditions to model the 60-min clinical PHP procedure.
The mean filter efficiency for removing melphalan in six filters was 99.0 ± 0.4 %. The transfilter pressure gradient across the filter averaged 20.9 mmHg for the 60-min procedure. Many blood components, including albumin and platelets, decreased on average from 3.55 to 2.02 g/dL and from 342 to 177 × 10.e3/μL, respectively, during the procedure.
The increased melphalan extraction efficiency of the new filter is expected to decrease systemic melphalan exposure. In addition, the low transfilter pressure gradient resulted in low resistance to blood flow in the GEN 2 filter, and the changes to blood components are expected to be clinically manageable.
Ausman RK (1961) Development of a technique for isolated perfusion of the liver. N Y State J Med 61:3993–3997 PubMed
Lin G, Lunderquist A, Hagerstrand I, Boijsen E (1984) Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 96(3):517–526 PubMed
Van De Velde CJH, Kothuis BJL, Barenbrug HWM et al (1985) A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res 41:593–599 CrossRef
Pinguet F, Culine S, Bressolle F et al (2000) A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res 6:57–63 PubMed
Hwu W, Salem R, Pollak J et al (1999) A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. Oncol Res 11:529–537 PubMed
Pingpank JF, Hughes MS, Alexander HR, et al (2010) A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol (Meeting Abstracts) 28(18 Suppl):LBA8512. http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA8512
- Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
Fred M. Moeslein
Elizabeth G. McAndrew
William M. Appling
Nicole E. Hryniewich
Kevin D. Jarvis
Steven M. Markos
Timothy P. Sheets
Rajneesh P. Uzgare
Daniel S. Johnston
- Springer US
Neu im Fachgebiet Radiologie
Meistgelesene Bücher aus der Radiologie
Mail Icon II